Sarepta Therapeutics Inc (SRPT)

126.29 +2.20 (+1.77%) USD  |  NASDAQ  |  Jan 03, 16:00
126.69 +0.40 (+0.32%) After-Hours: 04:20
More

Sarepta Therapeutics SG&A Expense (Quarterly): 128.20M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for SRPT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Arrowhead Pharmaceuticals Inc 25.79M
Alnylam Pharmaceuticals Inc 220.99M
Eli Lilly and Co 2.100B
Catalyst Pharmaceuticals Inc 45.88M
Vertex Pharmaceuticals Inc 371.80M